Does Phenobarbital Have a Longer Half-Life Than Lorazepam?
Yes, phenobarbital has a dramatically longer half-life than lorazepam—approximately 53-118 hours (mean 79 hours) for phenobarbital versus only 12 hours for lorazepam in adults.
Pharmacokinetic Comparison
Phenobarbital
- Half-life in adults: 53-118 hours (mean 79 hours) 1
- Half-life in children/newborns: 60-180 hours (mean 110 hours) 1
- Time to maximal CNS depression: 15 minutes or more after IV administration 1
- Protein binding: 20-45% 1
- Renal excretion: 25-50% eliminated unchanged in urine 1
Lorazepam
- Half-life: Approximately 12 hours for unconjugated lorazepam 2
- Metabolite half-life: 18 hours for lorazepam glucuronide 2
- Peak plasma concentration: ~2 hours after oral administration 2
- Protein binding: 85% 2
Clinical Implications
The 6-7 fold difference in half-life has major clinical consequences:
Phenobarbital's prolonged half-life means:
- Slower onset of peak sedative effect (15+ minutes IV) 1
- More sustained therapeutic levels with less frequent dosing
- Greater risk of drug accumulation with repeated dosing
- Longer time to steady state (typically 2-3 weeks)
- Prolonged duration of action and delayed emergence from sedation
Lorazepam's shorter half-life means:
- More rapid titratability for sedation control
- Less drug accumulation
- Faster clearance when discontinued
- However, active metabolites can accumulate in renal dysfunction, paradoxically prolonging effects 3
Context for ICU Sedation
While this pharmacokinetic difference exists, current ICU guidelines have moved away from benzodiazepines as first-line sedatives due to worse clinical outcomes. Studies comparing propofol or dexmedetomidine to lorazepam consistently showed that lorazepam resulted in more ventilator days, increased delirium, and worse mortality 4. The 2013 guidelines note that lorazepam has a slower clearance and greater potency than midazolam, with emergence from short-term sedation (1-2 days) being longer with lorazepam 3.
Important caveat: Lorazepam contains propylene glycol as a diluent, which can cause metabolic acidosis and acute kidney injury with prolonged infusions—a toxicity not seen with phenobarbital 3.
For alcohol withdrawal specifically, recent evidence suggests phenobarbital may offer advantages over benzodiazepines, with shorter hospital length of stay and reduced ICU requirements, despite its longer half-life 5.